<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230506058100N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-06-14</date_registration>
      <primary_sponsor>Iran University of Medical Sciences</primary_sponsor>
      <public_title>The incidence of rigid bronchoscopy complications in children with foreign body aspiration</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the incidence of rigid bronchoscopy complications with three anesthesia methods of spontaneous ventilation, controlled ventilation using Atracurium and controlled ventilation using Rocuronium in children with foreign body aspiration</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-04-30</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>63</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/70038</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this study, block randomization method with block size 4 is used. The website https://www.sealedenvelope.com is used to generate random sequences. Each of the randomly generated sequences contains a unique code for concealment. The randomized list is provided to one of the operating room personnel and he tells the researcher which group each patient should be placed in. Then the patients are assigned to 3 groups, Blinding description: Patient blinding: Patients are unaware of the treatment process due to their condition and they are unconscious.
Care giver blinding: in  3 groups, Propofol will be drawn into a syringe and connected to the infusion pump, but it will be injected only in the Propofol group. Propofol is distilled water, and in Rocuronium and Atracurium groups, the dose of the corresponding drug is the same, so it is not possible for the assistant data recorder and the person performing the bronchoscopy to distinguish the Propofol group from the other two groups.</study_design>
      <phase>3</phase>
      <hc_freetext>Foreign body aspiration.</hc_freetext>
      <i_freetext>Intervention 1: Group P or Propofol  : After induction of inhalation anesthesia with Sevoflurane, Propofol infusion is started at a dose of 80-100 mcg/kg/min, and the relaxant drug will not be injected, and after 3 minutes, rigid bronchoscopy is started. In this group, assisted breathing is given by controlling the ambobag and chest movements, and after the procedure, the drugs are removed. Intervention 2: Group R or Rocuronium: after induction of inhalation anesthesia with Sevoflurane, Rocuronium is injected at a dose of 0.3 mg/kg and bronchoscopy is started after 3 minutes, Propofol infusion is not performed in this group, and the oxygen line is connected through an interface next to the bronchoscope (T segment), and controlled breathing is given with an ambobag through the Mepleson D system. If the procedure is prolonged, and need to repeat the relaxant Rocuronium is prescribed at a dose of 0.2 mg /kg and 0.3 mg /kg. After the procedure, breathing with a face mask and oxygen and low dose Sevoflurane (1%) continues until the patient's breathing returns, and then Sevoflurane is stopped and reversed with Atropine 0.02 mg /kg and Neostigmine 0.05 mg/kg. Intervention 3: Group A or Atracurium: after induction of inhalation anesthesia with Sevoflurane, Atracurium is injected at a dose of 0.3 mg/kg and after 3 minutes' bronchoscopy is started. Propofol infusion is not performed in this group, and the oxygen line is connected through an interface next to the bronchoscope (T segment), and controlled breathing is given with an ambobag through the Mepleson D system. If the procedure is prolonged need to repeat the relaxant drug, Atracurium is prescribed at a dose of 0.2 and 0.3 mg /kg. After the procedure, breathing with a face mask and oxygen and low dose Sevoflurane (1%) continues until the patient's breathing returns, and then Sevoflurane is stopped and reversed with Atropine 0.02 mg /kg and neostigmine 0.05 mg/kg is done.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Tahereh Chavoshi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No.193, Zafar st, Moddares Highway</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1919816766</zip>
        <telephone>+98 21 2304 6253</telephone>
        <email>Chavoshi.t@iums.ac.ir</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Tahereh Chavoshi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No.193, Zafar st, Moddares Highway</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1919816766</zip>
        <telephone>+98 21 2304 6253</telephone>
        <email>Chavoshi.t@iums.ac.ir</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Parents' consent to participate in the study after bronchoscopy
Age range 1 to 6 years
Children with foreign body aspiration , if the foreign body is not in the upper part of the main airway and in the larynx or hypopharynx
They should be in ASA class 1 and 2</inclusion_criteria>
      <agemin>1 year</agemin>
      <agemax>6 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Emergency cases
Children with asthma and irritable airways
Airway anomaly
Drug allergy to any of the drugs used
Neurological disorders and seizures
kidney disease
Cardiovascular disease
Neuromuscular disorder
Metabolic disorder</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>T17.9</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Foreign body in respiratory tract, part unspecified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Surgery</i_code>
      <i_code>Treatment - Surgery</i_code>
      <i_code>Treatment - Surgery</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Group P or Propofol  : After induction of inhalation anesthesia with Sevoflurane, Propofol infusion is started at a dose of 80-100 mcg/kg/min, and the relaxant drug will not be injected, and after 3 minutes, rigid bronchoscopy is started. In this group, assisted breathing is given by controlling the ambobag and chest movements, and after the procedure, the drugs are removed.</i_keyword>
      <i_keyword>Group R or Rocuronium: after induction of inhalation anesthesia with Sevoflurane, Rocuronium is injected at a dose of 0.3 mg/kg and bronchoscopy is started after 3 minutes, Propofol infusion is not performed in this group, and the oxygen line is connected through an interface next to the bronchoscope (T segment), and controlled breathing is given with an ambobag through the Mepleson D system. If the procedure is prolonged, and need to repeat the relaxant Rocuronium is prescribed at a dose of 0.2 mg /kg and 0.3 mg /kg. After the procedure, breathing with a face mask and oxygen and low dose Sevoflurane (1%) continues until the patient's breathing returns, and then Sevoflurane is stopped and reversed with Atropine 0.02 mg /kg and Neostigmine 0.05 mg/kg.</i_keyword>
      <i_keyword>Group A or Atracurium: after induction of inhalation anesthesia with Sevoflurane, Atracurium is injected at a dose of 0.3 mg/kg and after 3 minutes' bronchoscopy is started. Propofol infusion is not performed in this group, and the oxygen line is connected through an interface next to the bronchoscope (T segment), and controlled breathing is given with an ambobag through the Mepleson D system. If the procedure is prolonged need to repeat the relaxant drug, Atracurium is prescribed at a dose of 0.2 and 0.3 mg /kg. After the procedure, breathing with a face mask and oxygen and low dose Sevoflurane (1%) continues until the patient's breathing returns, and then Sevoflurane is stopped and reversed with Atropine 0.02 mg /kg and neostigmine 0.05 mg/kg is done.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Laryngospasm. Timepoint: beginning of bronchoscopy to  end of anesthesia and the patient waking up. Method of measurement: Decreased oxygen saturation following epiglottis closure.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Iran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-04-17</approval_date>
        <contact_name>Ethics committee of Iran University of Medical Sciences</contact_name>
        <contact_address>Iran University of Medical Sciences; Next to the Milad Tower; Hemmat Highway Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
